604 zoekresultaten voor “drug discovery” in de Publieke website
-
Drug Discovery & Safety
In het onderzoeksprogramma Drug Discovery & Safety zijn we geïnteresseerd in de werkzaamheid en veiligheid van nieuwe medicijnen en nieuwe manieren om deze aspecten te bepalen. Daarvoor combineren we geavanceerde imaging en high-throughput screening technieken met computationele aanpakken zoals chem-…
-
Drug Discovery and Safety (MSc)
In deze opleiding ontwikkel je je onderzoek skills en verbreed je je kennis over de meest moderne en geavanceerde technieken die je nodig hebt als onderzoeker op het gebied van target finding en het ontwerp en de synthese van nieuwe geneesmiddelen.
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
Microengineered Human Blood Vessels For Next Generation Drug Discovery
Heart failure is a major health care problem with high mortality.
-
Proteins in harmony: Tuning selectivity in early drug discovery
This thesis describes the importance of being able to control the selectivity of potential drug candidates.
-
Assistant Professor in Artificial Intelligence and Structure-Based Drug Discovery
Leiden University, the Faculty of Science and the Leiden Academic Center for Drug Research are looking for an Assistant Professor in Artificial Intelligence and Structure-Based Drug Discovery
-
Transforming data into knowledge for intelligent decision-making in early drug discovery
Promotor: A.P.IJzerman Co-promotor: A. Bender
-
Image-based phenotypic screening for breast cancer metastasis drug target discovery
The main aim of this thesis was to unravel the signaling and regulatory networks that drive tumor cell migration during breast cancer metastasis.
-
13th LCDS meeting: combining data science and drug discovery
How can data science be used to discover new medicines? This was the central question of the LCDS meeting on data driven drug discovery on Friday, 10 June 2016.
-
Mechanistic modelling of drug target binding kinetics as determinant of the time course of drug action in vivo
Drug-target binding kinetics determine the time course of the central event in pharmacotherapy: Drug-target interaction.
-
Cancer Drug Discovery Initiative maakt nieuwe therapieën tegen kanker mogelijk
Het Antoni van Leeuwenhoek/Nederlands Kanker Instituut, het Leids Instituut voor de Chemie en het Pivot Park Screening Centre gaan kennis en infrastructuur delen in het Cancer Drug Discovery Initiative. Vrijdag 11 oktober tekenden ze een letter of intent.
-
Towards improved drug action : target binding kinetics and functional efficacy at the mGlu2 receptor
During the course of drug discovery translational steps are made.
-
Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia
The disease acute myeloid leukemia (AML) is characterized by fast progression and low survival rates.
-
Discovery of novel inhibitors to investigate diacylglycerol lipases and α/β hydrolase domain 16A
Promotor: H.S. Overkleeft, Co-promotor: M. van der Stelt
-
Time is of the essence: investigating kinetic interactions between drug, endogenous neuropeptides and receptor
Promotor: A.P. IJzerman Co-promotor: L.H. Heitman
-
Leiden Academic Centre for Drug Research
Het ontwikkelen van nieuwe medicijnen is een complex proces waarbij veel partijen samenwerken. De onderzoekers van het LACDR zetten zich dagelijks in voor nieuwe, betere, efficiëntere en makkelijker produceerbare medicijnen. Het instituut werkt nauw samen met het LUMC, met bedrijven op het Leiden Bio-Science…
-
NMR structural studies of protein-small molecule interactions
Promotor: Prof.dr. M. Ubbink, Co-promotor: G. Siegal
-
Erik Danen benoemd tot hoogleraar Cancer drug target discovery
Met ingang van 1 april 2018 is Erik Danen benoemd tot hoogleraar Cancer drug target discovery bij het Leiden Academic Centre for Drug Research (LACDR). Zijn vakgebied is celbiologie van kanker, waarin hij zich richt op de achterliggende mechanismen bij uitzaaiingen en resistentie voor behandelingen.
-
Medical Delta café: translation models for drug discovery and development, 8 oktober 2013
Onze gemiddelde leeftijd gaat omhoog en de behoefte naar goede gezondheidszorg wordt steeds groter. Nieuwe medicijnen moeten op de markt komen maar kosten voor de ontwikkeling daarvan moeten omlaag. Tijdens het Medical Delta café op 8 oktober presenteren o.a. dr. Leo Price, dr. Jan de Sonneville en…
-
Drug-target residence time: a case for the adenosine A1 and A2A receptors
Promotor: A.P.IJzerman, Co-Promotor: L.H. Heitman
-
namic Relationships of Central Nervous Systems Active Dopaminergic Drugs
Discovery and development of Central Nervous System (CNS) drugs is hampered by high attrition rates.
-
Mario van der SteltWiskunde en Natuurwetenschappen
-
Inhibitor discovery of phospholipases and N-acyltransferases
In this thesis an activity-based probe was discovered that could visualize the activity of PLAATs. With an optimized gel-based ABPP assay in hand, screening of a compound library led to the discovery of alpha-ketoamides as a hit for PLAAT3.
-
Biophysical characterization of membrane protein-small molecule interactions
Promotor: Prof.dr. M. Ubbink
-
Full professor in Discovery of Biologics
Wiskunde en Natuurwetenschappen, Leiden Academic Centre for Drug Research (LACDR)
-
Chemical tools to study the cannabinoid receptor type 2
The cannabinoid receptor type 2 (CB2R) is associated with several inflammatory diseases with an unmet medical need (e.g. Alzheimers, multiple sclerosis, reumatoid arthritis). Development of new chemical biology strategies to study this protein is essential to aid future development of drugs for these…
-
Photo-activated drug delivery systems
O-Nitrobenzyl groepen worden veel gebruikt als moleculaire beschermgroepen die je met licht kunt verwijderen.
-
Fluorescence Polarization Activity-Based Protein Profiling on Retaining Glycosidases
Glycosidases are important enzymes in the turnover of polysaccharides and glycoconjugates, and are involved in a range of human pathologies including genetic disorders such as Gaucher and Pompe disease, but also in various cancers.
-
Small changes for long term impact: optimization of structure kinetic properties: a case of CCR2 antagonists
Promotor: Prof.dr. A. P. IJzerman, Co-Promotor: L.H. Heitman
-
Dynamics of TNFalpha signaling and drug-related toxicity
In previous studies at our laboratory it was demonstrated that drug exposure of HepG2 cells can lead to an altered TNFα-induced NF-κB oscillatory phenotype, concurrent with a synergistically increased sensitivity for TNFα-induced apoptosis.
-
Clavis Aurea? Structure-enabled approaches of identifying and optimizing GPCR ligands
Promotores: A.P. IJzerman, H.W.T. van Vlijmen
-
Reverse engineering of drug induced QT(c) interval prolongation: Towards a systems pharmacology approach
Promotor: M. Danhof Co-promotor: O.E. Della Pasqua
-
13th LCDS meeting: Data-Driven Drug Discovery
Congres/symposium
-
Cancer drug target discovery
Oratie
-
The activation mechanisms of G protein-coupled receptors: the case of the adenosine A2B and HCA2/3 receptors
Promotor: A.P. IJzerman
-
Translational pharmacokinetics-pharmacodynamics in zebrafish: integration of experimental and computational methods
The zebrafish is a promising vertebrate model organism in early drug discovery and development.
-
Phenotypic screening with 3D cell-based assays
Traditional drug discovery approaches have been hampered by (in vitro) cell-culture models that poorly represent the situation in the human body.
-
Inhibitor Selectivity: Profiling and Prediction
Less than 1 in 10 drug candidates that enter phase 1 clinical trials actually gets approved for human use.
-
Chemical genetic approaches for target validation
Drug development is a time- and resource-consuming process that starts with the discovery and validation of a (protein) target that contributes to pathogenesis or disease progression.
- Onderzoek naar drugs (cannabis en XTC)
-
Prediction of spatial-temporal brain drug distribution with a novel mathematical model
A novel mathematical model describes spatial-temporal drug distribution within one or more brain units, which are cubic representations of a piece of brain tissue with brain capillaries at the edges.
-
Assistant Professor in Ligand and (Pro)Drug Development
Leiden University, the Faculty of Science and Leiden Academic Center for Drug Research are looking for an Assistant Professor in Ligand and (Pro)Drug Development
-
Targeting the adenosinergic system
Adenosine is an endogenous ligand which exerts its action by activating adenosine receptors (ARs), while its circulating levels are controlled via a variety of mechanism and proteins, amongst others the equilibrative nucleoside transporters (ENTs).
-
Advanced in vitro models for studying drug induced toxicity
Promotor: B.van de Water, Co-promotor: L.S.Price
-
Data-Driven Knowledge Discovery in Polycystic Kidney Disease
Promotie
-
Zebrafish embryos and larvae as a complementary model for behavioural research
Promotor: Prof.dr. M.K. Richardson
-
Illuminating N-acylethanolamine biosynthesis with new chemical tools
In this thesis, the discovery and optimization is described of chemical tools to study the N-acylethanolamine (NAE) biosynthetic pathway.
-
Bio-Pharmaceutical Sciences (MSc)
Deze opleiding wordt aangeboden door het Leiden Academic Centre for Drug Research en is gericht op onderzoek en ontwikkeling van geneesmiddelen. Het programma beslaat vrijwel het gehele gebied van het geneesmiddelenonderzoek en biedt studenten veel keuzevrijheid.
-
Knowledge Discovery and Data Mining from patient experience repositories
This project develops a scientific method to extract clinically relevant new information from patient forum websites that discuss patient experiences concerning e.g. medication, nutrition, co-morbidities, genetic factors etc.
-
NMR studies of protein-small molecule and protein-peptide interactions
Promotor: M. Ubbink, Co-promotor: G. Siegal